What are the short-term and long-term side effects of PDE5 inhibitors like sildenafil?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
PDE5 inhibitors such as sildenafil commonly cause short-term, reversible effects—headache, flushing, nasal congestion, dyspepsia and visual changes—which affect up to about 1 in 10 users for some symptoms and serious events are rare (<1 in 1,000) [1] [2]. Longer-term serious risks reported in the literature are mainly cardiovascular events in people with preexisting heart disease, rare prolonged erections (priapism), and possible persistent ocular events such as nonarteritic ischemic optic neuropathy (NAION) or prolonged visual disturbances reported in case series and reviews [3] [4] [5].
1. Short-term side effects: the common, expected reactions
Most people taking sildenafil experience transient, dose‑related symptoms that resolve within hours: headache, facial flushing, nasal congestion, indigestion, dizziness and back pain are the typical short-term complaints; many sources note these tend to occur more with higher doses and are usually mild to moderate [1] [6] [7]. Clinicians and drug information pages repeatedly advise that these effects frequently do not require stopping the drug and can be managed by dose adjustment [1] [7].
2. Short-term eye and hearing effects: reversible but concerning
Sildenafil can produce temporary visual disturbances—changes in color perception, increased light sensitivity, blurred vision and electroretinogram (ERG) alterations—because it weakly inhibits retinal PDE6; most trial and review data describe these ocular effects as transient and reversible at therapeutic doses, though recreational or excessive use increases risk [5]. Sudden loss or decrease of vision and sudden hearing loss are flagged as rare but serious reactions that warrant immediate medical attention [2] [4].
3. Cardiovascular and serious acute events: rare but medically important
Regulatory and clinical sources emphasize that severe cardiovascular events—heart attack, stroke, arrhythmia and syncope—have occurred predominantly in people with underlying heart disease; guidance is explicit that sildenafil can cause serious problems during sexual activity and should be used cautiously or avoided in patients on nitrates or with significant cardiac conditions [3] [4] [7]. The NHS and drug references quantify serious events as uncommon (<1 in 1,000) but advise urgent evaluation if chest pain or concerning cardiorespiratory symptoms develop [2] [4].
4. Priapism and hematologic cautions: rare but time-sensitive harms
Prolonged erection (priapism) is a recognised, uncommon adverse effect that can cause permanent damage if not treated promptly; people with sickle cell disease and other hematologic disorders are instructed to use sildenafil cautiously because their baseline risk of prolonged erections is higher [8]. Drug manuals and prescribing information highlight the need for emergency care if an erection persists beyond recommended limits [8] [9].
5. Long-term safety data: reassuring for most, but gaps remain
Long‑term clinical experience (over decades) shows sildenafil is generally safe when used as directed for erectile dysfunction or pulmonary hypertension, but published reviews, post‑marketing reports and specialist centers note rare but serious long‑term outcomes—cardiopulmonary events in vulnerable patients and persistent ocular events in case reports—without establishing direct causality in many instances [3] [5] [10]. StatPearls and clinical summaries also warn that higher-than-recommended doses increase side-effect frequency without improving efficacy [10].
6. Drug interactions and organ impairment amplify risk
Experts and drug databases stress that concurrent use of nitrates is an absolute contraindication because of profound hypotension; strong CYP3A4 inhibitors (ketoconazole, itraconazole, some HIV protease inhibitors) can sharply raise sildenafil blood levels and side-effect risk, and liver or renal impairment slows clearance, increasing adverse-event likelihood [9] [11] [8]. Providers should review other medicines and grapefruit consumption, which can raise sildenafil levels [6] [9].
7. What the evidence disagrees on and what is unsettled
Systematic clinical trials and product labels portray most ocular and cardiovascular events as rare and often reversible; in contrast, case series and literature reviews raise concern about NAION and persistent visual symptoms in some patients—these reports signal possible idiosyncratic harms but stop short of proving a causal chain at therapeutic dosing [5] [2]. Available sources do not mention definitive population-level increases in long-term mortality attributable solely to sildenafil (not found in current reporting).
8. Practical takeaways for patients and clinicians
Use the lowest effective dose, avoid nitrates and be cautious with strong CYP3A4 inhibitors and in liver/kidney disease; stop the drug and seek urgent care for sudden vision/hearing loss, chest pain, or an erection lasting more than 4 hours [8] [4] [2]. Report suspected side effects to local authorities or the FDA to improve post‑marketing surveillance [4].
Limitations: this summary synthesizes prescribing information, reviews and drug resources in the provided set; it does not include unpublished data or studies outside these sources and therefore cannot adjudicate causality for rare case reports beyond what the cited reviews state [5] [10].